Register Now!
Find a Speaker Event
or

Results

In-person events

Wednesday, January 22, 2025
6:00 PM EST

Out-of-Office Live

Speaker:

Shana Perman, PA-C

Location:

Craftsman Inn, 7300 East Genesee Street 13066, Fayetteville, NY 13066

Description:

Please join us for an engaging session tailored specifically for advanced practice providers and nurses. During this presentation, we will delve into the role of controlled ovarian stimulation in the assisted reproductive cycle and explore studies that highlight the clinical differences and advantages of using MENOPUR for controlled ovarian stimulation. This program aims to equip you with the knowledge to help facilitate the optimal use of MENOPUR in clinical practice.

Online events

Wednesday, January 15, 2025
12:00 PM CST

Hybrid (Speaker Remote)

Speaker:

Staci Gorson, MSN, APRN, FNP-BC

Location:

Aspire HFI Woodlands, 8850 Six Pines, The Woodlands, TX 77380

Description:

Please join us for an engaging session tailored specifically for advanced practice providers and nurses. During this presentation, we will delve into the role of controlled ovarian stimulation in the assisted reproductive cycle and explore studies that highlight the clinical differences and advantages of using MENOPUR for controlled ovarian stimulation. This program aims to equip you with the knowledge to help facilitate the optimal use of MENOPUR in clinical practice.

Back to Search
INDICATION AND IMPORTANT SAFETY INFORMATION
MENOPUR® (menotropins for injection)
INDICATION FOR USE
  • MENOPUR® (menotropins for injection), administered subcutaneously, is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an Assisted Reproductive Technology (ART) program.
IMPORTANT SAFETY INFORMATION
  • MENOPUR is contraindicated in women who have: a high FSH level indicating primary ovarian failure, presence of uncontrolled non-gonadal endocrinopathies, tumors of the pituitary gland or hypothalamus, sex hormone dependent tumors of the reproductive tract and accessory organs, abnormal uterine bleeding of undetermined origin, ovarian cysts or enlargement of undetermined origin, not due to polycystic ovary syndrome, or prior hypersensitivity to menotropins or MENOPUR. MENOPUR is not indicated in women who are pregnant and may cause fetal harm when administered to a pregnant woman

  • MENOPUR should only be used by physicians who are thoroughly familiar with infertility problems. MENOPUR is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Ovarian torsion has been reported after gonadotropin treatment. Serious pulmonary conditions and thromboembolic events have been reported with MENOPUR. There have been infrequent reports of ovarian neoplasms with MENOPUR. Multiple pregnancies, spontaneous abortion, congenital malformations and ectopic pregnancies have occurred following treatment with MENOPUR.

  • The most common adverse reactions (≥2%) in ART include: abdominal cramps; abdomen enlarged; abdominal pain; headache; injection site pain and reaction; injection site inflammation; OHSS.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 1.800.FDA.1088.

Please see full Prescribing Information.

Please see Important Safety Information and Full Prescribing Information